Medicamen Organics Limited (NSE SME)
Jun 21, 2024 - Jun 25, 2024
| Price | ₹32 - ₹34 |
| Premium | ₹70 |
|---|---|
| Lot size | 4000 |
| Allotment | Jun 26, 2024 |
| Listing | Jun 28, 2024 |
| Category | Lot(s) | Qty | Amount | Reserved |
|---|---|---|---|---|
| Retail | 1 | 4000 | 136000 | 257 |
| HNI | 2 | 8000 | 272000 | 110 |
Last updated on 25-Jun-2024 17:59:05
| Category | Offered | Applied | Times |
|---|---|---|---|
| QIB | 584000 | 101052000 | 173.03 |
| NIB | 440000 | 589452000 | 1339.66 |
| RETAIL | 1028000 | 1290688000 | 1255.53 |
| Total | 2052000 | 1981192000 | 965.49 |
| Retail Apps | 322672 | © IPO Premium | |
| HNI Interest Cost Per Share (7 Days) | |||||
|---|---|---|---|---|---|
| @7% ₹61.15 | @8% ₹69.88 | @9% ₹78.62 | @10% ₹87.35 | @11% ₹96.09 | @12% ₹104.82 |
Medicamen Organics IPO Reservation
| Investor Category | Shares Offered | No. of Shares |
|---|---|---|
| Retail | 33.16% | 1028000 |
| NII (HNI) | 14.19% | 440000 |
| Anchor | 28.26% | 876000 |
| QIB | 18.84% | 584000 |
| Market Maker | 5.55% | 172000 |
| Total | 100.00% | 3100000 |
Medicamen Organics IPO Details
| Issue Size | 3,100,000 shares (aggregating up to ₹10.54 Cr) |
| Fresh Issue | 3,100,000 shares (aggregating up to ₹10.54 Cr) |
| Issue Type | Book Built Issue IPO |
| Listing At | NSE SME |
| Share holding pre issue | 8,600,000 |
| Share holding post issue | 11,700,000 |
| Market Maker portion | 172,000 shares Giriraj Stock Broking |
Key Performance Indicator
| KPI | Sep-23 | Mar-23 | Mar-22 |
|---|---|---|---|
| ROCE | 9.21% | 9.71% | 4.09% |
| RONW | 10.93% | 11.25% | 1.22% |
| D/E | 0.90 | 1.38 | 1.36 |
| EPS (Diluted) | 1.89 | 1.60 | 0.15 |
| P/E Pre IPO | 30.53 | ||
| P/E Post IPO | 15.41 |
Company Financials
Medicamen Organics Limited Financial Information (Restated)
Medicamen Organics Limited's revenue increased by 8.38% and profit after tax (PAT) rose by 937.7% between the financial year ending with March 31, 2023 and March 31, 2022.
| Period | Sep 2023 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|
| Assets | 3,450.88 | 3,211.98 | 2,707.21 | 2,634.37 |
| Revenue | 1,132.60 | 2,296.24 | 2,118.67 | 2,505.96 |
| Profit | 129.11 | 95.78 | 9.23 | 29.81 |
| Net Worth | 1,180.83 | 851.71 | 755.92 | 746.72 |
| Reserves | 380.83 | 251.71 | 155.92 | 146.72 |
| Borrowing | 1,062.50 | 1,179.50 | 1,024.57 | 958.97 |
| Amount in ₹ Lakhs | ||||
About Company
Incorporated in 1995, Medicamen Organics Limited develops, manufactures, and distributes a wide range of pharmaceutical dosages, including tablets, capsules, oral liquids, ointments, gels, syrups, suspensions, and dry powders. Serving both government and private entities as a contract/third-party manufacturer, the company offers 84 products spanning various drug categories such as antibacterial, antidiarrheal, antifungal, antimalarial, antidiabetic, proton pump inhibitors, antihistamines, antihypertensive drugs, lipid preparations, antiparasitics, multivitamin preparations, multimineral, and NSAIDs. Medicamen Organics markets its products across India and internationally in African, CIS, and Southeast Asian countries, including Congo, Benin, Kameg, Togo, Senegal, Burkina Faso, Philippines, Myanmar, Mozambique, Togo, Burundi, Kyrgyzstan, and Kenya through third-party distributors. The company operates two WHO-GMP-approved manufacturing facilities in Haridwar, Uttarakhand, covering 21,536 square feet. As of September 30, 2023, Medicamen Organics has partnered with 38 domestic contract manufacturers and 12 merchant exporters, employing a total of 116 people.
Strength Factors
Experienced Promoters and Management Team: Medicamen Organics Limited benefits from the guidance of seasoned promoters and a skilled management team, ensuring strategic direction and effective decision-making.
Long-Standing Customer Relationships: The Company has established and maintained enduring relationships with customers, fostering trust and consistent demand for its products.
Efficient Operational Team: With an efficient operational team, Medicamen Organics ensures high productivity and quality in its manufacturing processes, supporting its reputation and reliability in the pharmaceutical industry.
Risk Factors
Regulatory Approvals and Compliance: The Company requires various approvals, licenses, registrations, and permits for its operations. Any failure or delay in obtaining these in a timely manner could adversely affect its business activities.
Raw Material Price Fluctuations: Medicamen Organics is exposed to price fluctuations of raw materials, which can impact production costs and overall profitability.
Customer Concentration Risk: the Company’s dependency on a limited number of customers for sales means that losing any major customer could significantly affect its revenues and profitability.
Medicamen Organics IPO Lead Manager(s)
- GYR Capital Advisors Private Limited
Kfin Technologies Limited
Phone: 04067162222, 04079611000
Email: medicamen.ipo@kfintech.com
Website: https://kosmic.kfintech.com/ipostatus/